Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study

Phase Ii ◽

Phase Ii Trial ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with advanced epithelial ovarian cancer. A phase II trial of sequential doublets. (GO-FIRST)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.5034 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5034-5034 ◽

Cited By ~ 1

Author(s):

K. Chrystal ◽

C. B. Steer ◽

K. A. Cheong ◽

E. Galani ◽

A. Strickland ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with advanced epithelial ovarian cancer. A phase II trial of sequential doublets. (GO-FIRST)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.5034 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5034-5034

Author(s):

K. Chrystal ◽

C. B. Steer ◽

K. A. Cheong ◽

E. Galani ◽

A. Strickland ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

COMPARISON OF IFOSFAMIDE VERSUS CYCLOPHOSPHAMIDE IN COMBINATION WITH CISPLATIN AND DOXORUBICIN (ADRIAMYCIN), AS FIRST-LINE THERAPY FOR ADVANCED EPITHELIAL OVARIAN-CANCER - REPORT OF A PILOT-STUDY

Oncology Reports ◽

10.3892/or.1.3.631 ◽

1994 ◽

Author(s):

RE HEMPLING ◽

MS PIVER ◽

TR BAKER ◽

AM STANTON ◽

DL DRISCOLL

Keyword(s):

Ovarian Cancer ◽

Pilot Study ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Preliminary results from phase II trial of pembrolizumab with first line platinum based chemotherapy followed by maintenance pembrolizumab for patients with suboptimally cytoreduced advanced epithelial ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.05.202 ◽

2020 ◽

Vol 159 ◽

pp. 146-147

Author(s):

D. Uyar ◽

C.M. Michener ◽

W.H. Bradley ◽

E. Bishop ◽

P.G. Rose ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

First Line ◽

Preliminary Results ◽

Platinum Based Chemotherapy ◽

Weekly paclitaxel and carboplatin followed by topotecan (TC-TP), as first-line therapy for patients with advanced epithelial ovarian cancer (AOC) suboptimally debulked. Updated preliminary results

European Journal of Cancer ◽

10.1016/s0959-8049(01)81458-1 ◽

2001 ◽

Vol 37 ◽

pp. S260-S261

Author(s):

J.A. Arranz Arija ◽

R. Gonzalez-Beca ◽

A. Velasco ◽

M.M. Perez ◽

P. Borrega ◽

...

Keyword(s):

Ovarian Cancer ◽

Weekly Paclitaxel ◽

First Line ◽

Preliminary Results ◽

First Line Therapy ◽

Line Therapy ◽

Phase II Trial of Topotecan, Carboplatin, and Paclitaxel as Front-Line Therapy in Suboptimal Advanced Epithelial Ovarian Cancer

Gynecologic Oncology ◽

10.1006/gyno.2001.6179 ◽

2001 ◽

Vol 81 (2) ◽

pp. 331-333 ◽

Cited By ~ 9

Author(s):

G. Bolis ◽

G. Scarfone ◽

A. Villa ◽

F. Parazzini

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Front Line ◽

Line Therapy ◽

Use of OvaRex(r) MAb-b43.13 as an immunotherapeutic treatment of epithelial ovarian cancer: experience as single agent post first-line therapy and in combination with chemotherapy in recurrent disease

European Journal of Cancer ◽

10.1016/s0959-8049(02)81106-6 ◽

2002 ◽

Vol 38 ◽

pp. S137

Keyword(s):

Ovarian Cancer ◽

Recurrent Disease ◽

Single Agent ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Cancer Experience

Phase I Trial of Carboplatin, Paclitaxel, Etoposide, and Cyclophosphamide with Granulocyte Colony Stimulating Factor as First-Line Therapy for Patients with Advanced Epithelial Ovarian Cancer

Gynecologic Oncology ◽

10.1006/gyno.2000.5778 ◽

2000 ◽

Vol 77 (2) ◽

pp. 271-277 ◽

Cited By ~ 4

Author(s):

Nadine Tung ◽

Ross Berkowitz ◽

Ursula Matulonis ◽

Marc Quartulli ◽

Michael Seiden ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Phase I Trial ◽

Granulocyte Colony Stimulating Factor ◽

Colony Stimulating Factor ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Advanced Epithelial Ovarian Cancer ◽

Stimulating Factor

672 Randomised phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90703-8 ◽

2003 ◽

Vol 1 (5) ◽

pp. S202 ◽

Cited By ~ 15

Author(s):

J.-M. Extra ◽

F. Cognetti ◽

S. Chan ◽

D. Maraninchi ◽

R. Snyder ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Line Therapy

Randomized, Multi-center Phase II Trial of Docetaxel Plus Cisplatin Versus Etoposide Plus Cisplatin as the First-line Therapy for Patients with Advanced Non-Small Cell Lung Cancer

Cancer Research and Treatment ◽

10.4143/crt.2005.37.6.332 ◽

2005 ◽

Vol 37 (6) ◽

pp. 332

Author(s):

Nam-Su Lee ◽

Hee-Sook Park ◽

Jong-Ho Won ◽

Dae-Sik Hong ◽

Su-Taek Uh ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy